

Nanologica Q3 2023 - Untapped Potential

Redeye returns with a research update on Nanologica following its Q3 2023 report, which were soft in terms of sales but in line with our EBIT estimate. With an eventful period in terms of customer activity, we see an exciting period ahead.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Nanologica Q3 2023 - Untapped Potential